AU Patent

AU2010245097B2 — Methods of treating bacterial infections using oritavancin

Assigned to Melinta Subsidiary Corp · Expires 2015-08-13 · 11y expired

What this patent protects

The present invention is directed to methods of treating a bacterial infection in a subject through the administration of a therapeutically effective amount of a glycopeptide antibiotic to a subject having a bacterial infection. The effective amount of the glycopeptide antibiotic…

USPTO Abstract

The present invention is directed to methods of treating a bacterial infection in a subject through the administration of a therapeutically effective amount of a glycopeptide antibiotic to a subject having a bacterial infection. The effective amount of the glycopeptide antibiotic that is administered to the subject provides a fraction of the glycopeptide antibiotic administered to the subject bound to serum proteins within the subject and within a selected range.

Drugs covered by this patent

Patent Metadata

Patent number
AU2010245097B2
Jurisdiction
AU
Classification
Expires
2015-08-13
Drug substance claim
No
Drug product claim
No
Assignee
Melinta Subsidiary Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.